As of June 20, 2025, Hunan Fangsheng Pharmaceutical Co Ltd (603998.SS) reports a Net Margin of 14.36%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Hunan Fangsheng Pharmaceutical Co Ltd's Net Margin
Over recent years, Hunan Fangsheng Pharmaceutical Co Ltd's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 14.36% |
| 2023-12-31 | 11.47% |
| 2022-12-31 | 15.95% |
| 2021-12-31 | 4.47% |
| 2020-12-31 | 4.99% |
This slight downward trend highlights how Hunan Fangsheng Pharmaceutical Co Ltd manages its overall profitability and cost control over time.
Comparing Hunan Fangsheng Pharmaceutical Co Ltd's Net Margin to Peers
To better understand Hunan Fangsheng Pharmaceutical Co Ltd's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Hunan Fangsheng Pharmaceutical Co Ltd (603998.SS) | 14.36% |
| Hunan Hansen Pharmaceutical Co Ltd (002412.SZ) | 21.93% |
| Tibet Weixinkang Medicine Co Ltd (603676.SS) | 18.93% |
| Jinghua Pharmaceutical Group Co Ltd (002349.SZ) | 15.17% |
| Tianjin Lisheng Pharmaceutical Co Ltd (002393.SZ) | 13.81% |
| Ginwa Enterprise Group Inc (600080.SS) | 12.74% |
Compared to its competitors, Hunan Fangsheng Pharmaceutical Co Ltd's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.